Summary
89%
Pharmacokinetic
|
0% | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Alimemazin |
Scores | -6% | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
QT time prolongation
| |||||||||||
Anticholinergic effects
| |||||||||||
Serotonergic effects
|
Adverse drug events
|
-5% | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Leukopenia | |||||||||||
Hypotension | |||||||||||
Photosensitivity |
Variants ✨
For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Pharmacokinetics
-0%
∑ Exposurea | ali | |
---|---|---|
Alimemazin | 1 |
Legend (n.a.): Information not available
Since only alimemazin was entered without any further substances, no pharmacokinetic interactions can be detected.
Rating:
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability, half-life, and volume of distribution of alimemazin are unknown to us.
Serotonergic effects
-0%
Scores | ∑ Points | ali |
---|---|---|
Serotonergic Effects a | 0 | Ø |
Rating: According to our knowledge, alimemazin does not increase serotonergic activity.
Anticholinergic effects
-5%
Scores | ∑ Points | ali |
---|---|---|
Kiesel b | 2 | ++ |
Recommendation: As a precaution, attention should be paid to anticholinergic symptoms, especially after increasing the dose and at doses in the upper therapeutic range.
Rating: Alimemazin modulates the anticholinergic system to a moderate extent. The risk of anticholinergic syndrome with this medication is rather low if the dosage is in the usual range.
QT time prolongation
-1%
Scores | ∑ Points | ali |
---|---|---|
RISK-PATH c | 0.5 | ++ |
Alimemazin can potentially increase QT time, but we do not know about torsades de pointes arrhythmias.
General adverse effects
-5%
Side effects | ∑ frequency | ali |
---|---|---|
Leukopenia | 30.0 % | 30.0 |
Hypotension | 1.0 % | + |
Photosensitivity | 1.0 % | + |
Rash | 1.0 % | + |
Hyperprolactinemia | 1.0 % | + |
Dizziness | 1.0 % | + |
Dystonia | 1.0 % | + |
Insomnia | 1.0 % | + |
Agranulocytosis | 0.0 % | 0.0 |
Jaundice | 0.0 % | 0.0 |
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Neurological
Neuroleptic malignant syndrome: alimemazin
Limitations
Based on your
References
No literature information available.